| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥148.46B | ¥141.21B | +5.1% |
| Cost of Sales | ¥138.08B | ¥130.88B | +5.5% |
| Gross Profit | ¥10.38B | ¥10.33B | +0.5% |
| SG&A Expenses | ¥9.47B | ¥9.25B | +2.3% |
| Operating Income | ¥910M | ¥1.08B | -15.6% |
| Non-operating Income | ¥480M | ¥410M | +17.1% |
| Non-operating Expenses | ¥85M | ¥83M | +2.4% |
| Ordinary Income | ¥1.30B | ¥1.40B | -7.1% |
| Profit Before Tax | ¥1.82B | ¥1.39B | +30.7% |
| Income Tax Expense | ¥673M | ¥505M | +33.3% |
| Net Income | ¥1.14B | ¥884M | +29.4% |
| Net Income Attributable to Owners | ¥1.14B | ¥884M | +29.4% |
| Total Comprehensive Income | ¥1.70B | ¥733M | +131.2% |
| Depreciation & Amortization | ¥576M | ¥526M | +9.5% |
| Interest Expense | ¥0 | ¥0 | - |
| Basic EPS | ¥54.44 | ¥41.26 | +31.9% |
| Dividend Per Share | ¥10.00 | ¥10.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥112.08B | ¥103.82B | +¥8.26B |
| Cash and Deposits | ¥21.38B | ¥17.74B | +¥3.64B |
| Accounts Receivable | ¥61.63B | ¥58.78B | +¥2.85B |
| Inventories | ¥20.79B | ¥19.11B | +¥1.67B |
| Non-current Assets | ¥45.38B | ¥43.63B | +¥1.75B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥4.75B | ¥2.30B | +¥2.45B |
| Investing Cash Flow | ¥-856M | ¥-1.30B | +¥449M |
| Financing Cash Flow | ¥-249M | ¥-696M | +¥447M |
| Free Cash Flow | ¥3.89B | - | - |
| Item | Value |
|---|---|
| Book Value Per Share | ¥3,013.27 |
| Net Profit Margin | 0.8% |
| Gross Profit Margin | 7.0% |
| Current Ratio | 123.4% |
| Quick Ratio | 100.5% |
| Debt-to-Equity Ratio | 1.49x |
| EBITDA Margin | 1.0% |
| Effective Tax Rate | 37.0% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +5.1% |
| Operating Income YoY Change | -15.6% |
| Ordinary Income YoY Change | -7.1% |
| Net Income Attributable to Owners YoY Change | +29.4% |
| Total Comprehensive Income YoY Change | +131.2% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 24.40M shares |
| Treasury Stock | 3.38M shares |
| Average Shares Outstanding | 21.02M shares |
| Book Value Per Share | ¥3,014.03 |
| EBITDA | ¥1.49B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥10.00 |
| Year-End Dividend | ¥10.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DispensingIndustry | ¥6.29B | ¥8M |
| InformationAndCommunicationTechnologyIndustry | ¥1.05B | ¥59M |
| MedicalEquipmentWholesaleIndustry | ¥33.67B | ¥354M |
| NursingIndustry | ¥2.21B | ¥180M |
| WholesalerOfDrugsIndustry | ¥110.16B | ¥636M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥298.70B |
| Operating Income Forecast | ¥2.50B |
| Ordinary Income Forecast | ¥3.10B |
| Net Income Attributable to Owners Forecast | ¥1.90B |
| Basic EPS Forecast | ¥90.40 |
| Dividend Per Share Forecast | ¥10.00 |
| Property, Plant & Equipment | ¥24.58B | ¥23.62B | +¥959M |
| Intangible Assets | ¥1.61B | ¥1.48B | +¥132M |
| Goodwill | ¥636M | ¥690M | ¥-54M |
| Investment Securities | ¥17.71B | ¥17.04B | +¥674M |
| Total Assets | ¥157.46B | ¥147.45B | +¥10.01B |
| Current Liabilities | ¥90.85B | ¥82.35B | +¥8.50B |
| Accounts Payable | ¥82.85B | ¥75.00B | +¥7.85B |
| Non-current Liabilities | ¥3.26B | ¥3.24B | +¥16M |
| Long-term Loans | ¥10M | ¥11M | ¥-1M |
| Total Liabilities | ¥94.11B | ¥85.59B | +¥8.52B |
| Total Equity | ¥63.35B | ¥61.86B | +¥1.49B |
| Capital Stock | ¥1.00B | ¥1.00B | ¥0 |
| Capital Surplus | ¥11.82B | ¥11.82B | ¥0 |
| Retained Earnings | ¥45.95B | ¥45.02B | +¥934M |
| Treasury Stock | ¥-2.46B | ¥-2.46B | ¥0 |
| Owners' Equity | ¥63.33B | ¥61.84B | +¥1.48B |
| Working Capital | ¥21.23B | - | - |